ofloxacin has been researched along with gatifloxacin in 215 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (2.79) | 18.2507 |
| 2000's | 158 (73.49) | 29.6817 |
| 2010's | 46 (21.40) | 24.3611 |
| 2020's | 5 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Keserü, GM | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Aubry, A; Cambau, E; Jarlier, V; Matrat, S; Petrella, S; Sougakoff, W | 1 |
| Acosta, CJ; Agtini, M; Albert, MJ; Anh, DD; Arjyal, A; Basnyat, B; Bhattacharya, SK; Bhutta, ZA; Campbell, JI; Canh, DG; Chau, TT; Chinh, NT; Clemens, JD; Diep, TS; Dolecek, C; Dong, B; Dougan, G; Dutta, S; Farrar, J; Galindo, CM; Hien, TT; Honghui, Y; La, TT; Naheed, A; Newton, PN; Nga, TT; Ochiai, RL; Page, AL; Parry, CM; Phetsouvanh, R; Phuong, LT; Rang, NN; Schultsz, C; Tuan, PQ; Van Be Bay, P; Van Minh Hoang, N; Van Vinh Chau, N; Vinh, H; von Seidlein, L; Wain, J | 1 |
| Andres, P; Centrón, D; Galas, M; Guerriero, L; Petroni, A; Quiroga, C; Quiroga, MP; Soler Bistué, AJ; Tokumoto, M; Tolmasky, ME; Vargas, LJ; Zorreguieta, A | 1 |
| Aubry, A; Cambau, E; Jarlier, V; Matrat, S | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| Cattoir, V; Nordmann, P; Poirel, L | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chhasatia, MR; Gandhi, DS; Patel, MN | 1 |
| da Silva, PA; Hoffner, S; Jureen, P; Martin, A; Palomino, JC; Portaels, F; Vandamme, P; Von Groll, A | 1 |
| Martínez, JL; Sánchez, MB | 1 |
| Avdeef, A; Sun, N; Tam, KY; Tsinman, O | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Sen, S; Sinha, N | 1 |
| Anquetin, G; Aubry, A; Capton, E; Gomez, C; Jarlier, V; Lamouri, A; Pantel, A; Ponien, P; Serradji, N | 1 |
| Imai, YN; Oiki, S; Ryu, S | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Cheng, XW; Fan, YL; Feng, LS; Wu, JB; Zhang, FZ | 1 |
| Blaskovich, MAT; Pham, TDM; Ziora, ZM | 1 |
| Dhawan, S; Girase, PS; Karpoormath, R; Kumar, V; Palkar, MB; Shinde, SR | 1 |
| Bhagwat, S; Bhawsar, S; Deshpande, P; Joshi, S; Patel, M; Yeole, R | 1 |
| Aoyama, H; Fukuda, H; Hirai, K; Hosaka, M; Tomizawa, H; Yasue, T | 1 |
| Saito, H; Sato, K; Tomioka, H | 1 |
| Bauernfeind, A | 1 |
| Appelbaum, PC; Hoellman, DB; Jacobs, MR; Lin, G | 1 |
| Brisse, S; Fluit, AC; Köhrer, K; Martin, N; Milatovic, D; Scheuring, S; Schmitz, FJ; Verhoef, J | 1 |
| Akaki, T; Kajitani, H; Kawahara, S; Sakatani, M; Sato, K; Tomioka, H | 1 |
| Hershberger, E; Rybak, MJ | 1 |
| Bjarnason, J; Blondeau, JM; Laskowski, R; Stewart, C | 1 |
| Edmond, M; Heinemann, B; Seifert, H; Wisplinghoff, H | 1 |
| Ferraro, MJ; Jorgensen, JH; Swenson, JM; Tenover, FC; Weigel, LM; Whitney, CG | 1 |
| Hollauer, K; Kirchbauer, D; Naber, KG; Witte, W | 1 |
| Ambrose, PG; Grasela, DM | 1 |
| Baumgartner, T; Douglas, JM; Hook, EW; Jones, R; Leone, P; Martin, DH; McCormack, WM; Mroczkowski, TF; Stoner, BP; Yang, J | 1 |
| Jones, RN; Pfaller, MA | 1 |
| Biedenbach, DJ; Jones, RN; Pfaller, MA | 1 |
| Breen, JD; Brown, MJ; Champlin, J; Jones, TM; Miskin, BM; Tarshis, GA; Wingert, KJ | 1 |
| Bonner, DP; Fung-Tomc, J; Gradelski, E; Huczko, E; Minassian, B | 1 |
| Mendes, CM; Nicodemo, AC; Oplustil, CP; Sinto, S | 1 |
| Boos, M; Fluit, AC; Hafner, D; Jagusch, H; Mayer, S; Schmitz, FJ; Verhoef, J | 1 |
| Beach, ML; Jones, RN; Pfaller, MA | 1 |
| Ambrose, PG; Nicolau, DP | 1 |
| Frothingham, R | 2 |
| Calvo, A; García, R; Gómez-Lus, ML; Leturia, A; Sevillano, D; Valero, E | 1 |
| Karenchak, LM; Kowalski, RP; Mather, R; Romanowski, EG | 1 |
| Bosso, JA; Enzweiler, KA; Friedrich, LV; Hoban, D; Wagner, D; White, RL | 1 |
| Schaeffer, AJ | 1 |
| Appelbaum, PC; Bozdogan, B; Browne, FA; Clark, C; Dewasse, BE; Jacobs, MR | 1 |
| López, M; Rodríguez, JC; Royo, G; Ruiz, M | 1 |
| De Vecchi, E; Drago, L; Gismondo, MR; Lombardi, A; Nicola, L; Valli, M | 1 |
| Cheong, HJ; Choo, YS; Kang, MW; Kim, WJ; Kim, YS; Lee, KW; Park, YJ; Woo, JH; Yong, DE | 1 |
| Ambrose, PG; Bhavnani, SM; Jones, RN; Rubino, CM | 1 |
| Araake, M; Hara, T; Nishino, T; Watabe, H | 1 |
| Araake, M; Hara, T; Nishino, T; Shimizu, M; Tabata, M; Watabe, H | 1 |
| Hasegawa, M; Kobayashi, I; Matsuzaki, K; Sato, Y; Shikano, M; Watabe, E; Yoshimori, K | 1 |
| Araake, M; Maebashi, K; Tani, M; Watabe, H | 1 |
| Bello, S; Torres, A | 1 |
| López, M; Rodriguez Díaz, JC; Royo, G; Ruiz, M | 1 |
| Chiang, SR; Chuang, YC; Ko, WC; Lee, HC; Tang, HJ; Wang, YY | 1 |
| Ameyama, S; Shinmura, Y; Takahata, M | 1 |
| Carpenter, TR; Kaufman, MB; McDonnell, PJ; Sarayba, MA; Sweet, PM; Taban, M; Tungsiripat, T | 1 |
| Doganay, M; Esel, D; Sumerkan, B | 1 |
| Cai, S; Kamei, T; Ogasawara, K; Sano, C; Sano, K; Sato, K; Shimizu, T; Tomioka, H | 1 |
| Bosso, JA; Enzweiler, KA; White, RL | 1 |
| Piddock, L; Ricci, V | 1 |
| Dhaliwal, DK; Gordon, YJ; Karenchak, LM; Kowalski, RP; Mah, FS; Ritterband, DC; Romanowski, EG | 1 |
| Ebisu, H; Fukuda, H; Kishii, R; Takei, M | 1 |
| Almaraz, F; Baquero, F; Cantón, R; Jones, RN; Loza, E; Martín, R; Morosini, MI; Pascual, A; Perea, E; Tubau, F | 1 |
| Leggett, J; Saravolatz, LD | 1 |
| Garrison, MW; Madaras-Kelly, KJ; Schimmels, JA | 1 |
| Hong, JW; Hu, CQ; Sheng, LS | 1 |
| Gaynes, R; Johnson, TM; Killgore, G; Killum, E; Lowery, HK; Rimland, D; Tenover, FC | 1 |
| Hwang, DG | 1 |
| Acharya, B; Arakawa, S; Gotoh, A; Hinata, N; Kamidono, S; Kawabata, M; Kinoshita, S; Kofuku, T; Okada, H; Shigemura, K; Shirakawa, T | 1 |
| Daschner, F; Schmidt-Eisenlohr, E; Wenzler, S | 1 |
| Martinez, FJ | 1 |
| Bernabo, J; Eiguchi, K; Farinati, A; Miller, RD; Molestina, RE; Ramirez, JA; Summersgill, JT; Uriarte, SM | 1 |
| Blanchard, J; Lane, LC; Levine, JM; Noecker, RJ; Rapedius, M; Snyder, RW | 1 |
| Fukuda, Y; Hirakata, Y; Kadota, J; Kohno, S; Miyazaki, Y; Murata, I; Tashiro, T; Tomono, K; Tsukamoto, K; Yanagihara, K | 1 |
| Schooley, S; Stein, GE | 1 |
| Gonoi, T; Saraya, A; Seino, S; Yokokura, M | 1 |
| Greisman, J; Hoban, CJ; Hoban, DJ; Noreddin, AM; Schurek, KN; Siemens, CG; Smith, HJ; Zhanel, GG | 1 |
| Go, ES; Khurana, A; Recco, RA; Vinayek, N; Zaman, MM | 1 |
| Ba, BB; Grellet, J; Nguyen, HA; Quentin, C; Saux, MC | 1 |
| García-Tapia, A; Rodríguez, JC; Royo, G; Ruiz, M | 1 |
| Hoepelman, I | 1 |
| Burgess, DS; Frei, CR; Moczygemba, LR | 1 |
| Hermsen, ED; Hovde, LB; Konstantinides, GN; Rotschafer, JC | 1 |
| Hasegawa, M; Kobayashi, I; Koyama, H; Matsuzaki, K; Sato, Y; Watabe, E | 1 |
| Berger, RE | 1 |
| Paramasivan, CN; Rahman, F; Sulochana, S | 1 |
| Baltch, AL; Bopp, LH; Michelsen, PB; Ritz, WJ; Smith, RP | 1 |
| Anon, JB | 1 |
| Hoban, DJ; Noreddin, AM; Zhanel, GG | 1 |
| Kassab, NM; Kedor-Hackmam, ER; Santoro, MI; Singh, AK | 1 |
| Graff, JM; Kesler-Diaz, A; McDonnell, PJ; Osann, KE; Reiser, BJ; Sarayba, MA; Shamie, N; Sweet, PM; Taban, M | 1 |
| Abelson, MB; Shapiro, A; Torkildsen, G; Wagner, RS | 1 |
| Burgess, DS; Frei, CR | 1 |
| Aldag, JC; Avelino, RR; Gaddamanugu, M; Graumlich, JF; Habis, S; Jamma, K; Salverson, SM | 1 |
| Kenton, I; McKinnon, PS; Mohr, JF; Okhuysen, PC; Peymann, PJ; Septimus, E | 1 |
| Garrison, MW | 1 |
| Guo, H; Li, J; Liu, Z; Nie, S; Pan, W | 1 |
| Fukuda, H; Hayashi, K; Kadowaki, SE; Takei, M | 1 |
| Anguita-Alonso, P; Jacofsky, DJ; Osmon, DR; Patel, R; Piper, KE; Rouse, MS | 1 |
| Cornish, W; Knowles, S; Phillips, EJ; Rachlis, A; Simor, AE; Tailor, SA | 1 |
| Wang, S; Wang, Y; Yu, K | 1 |
| Dresser, L; Juurlink, DN; Kopp, A; Low, DE; Mamdani, MM; Park-Wyllie, LY; Shah, BR; Stukel, TA; Stumpo, C | 1 |
| Appelbaum, PC; Bozdogan, B; Choi, DR; Credito, K; Dewasse, B; Kosowska-Shick, K; Lin, G; McGhee, P; Pankuch, GA; Ryu, JM | 1 |
| Bosso, JA; Mauldin, PD | 1 |
| Black, JA; Moland, ES; Thomson, KS; Wickman, PA | 1 |
| Eiland, E; Hassoun, A | 1 |
| Aydemir, S; Cilli, F; Tunger, A | 1 |
| Baeyens, WR; Ouyang, J; Yang, Y; Zhao, H; Zhou, S | 1 |
| Boom, WH; Charlebois, ED; Daley, CL; Debanne, SM; Dietze, R; Eisenach, KD; Hadad, DJ; Jankus, DD; Johnson, JL; Maciel, E; Palaci, M; Peloquin, CA | 1 |
| Dhalla, IA; Juurlink, DN; Kopp, A; Mamdani, MM; Rochon, PA; Simor, AE | 1 |
| Amarnath, SK; Joshi, S | 1 |
| Asbell, PA; Bottone, EJ; Epstein, SP | 1 |
| Cole, J; Mathews, S; Ryono, RA | 1 |
| Gorman, PH; Johnson, JA; Roghmann, MC; Wallin, MT | 1 |
| Blondeau, JM; Blondeau, LD; Borsos, S; Hesje, C | 1 |
| Black, JA; Hanson, ND; Smith Moland, E; Thomson, KS; Wickman, PA | 1 |
| Adam, HJ; Baudry, TJ; Hoban, CJ; Hoban, DJ; Laing, NM; Nichol, KA; Schurek, KN; Zhanel, GG | 1 |
| Fiscella, RG; Jensen, MK | 1 |
| Kobayakawa, S; Shimizu, K; Tochikubo, T; Tsuji, A | 1 |
| Rodríguez, JC; Royo, G; Ruiz, M; Sirvent, E | 1 |
| Harish, BN; Menezes, GA; Parija, SC; Sarangapani, K | 1 |
| D'Azevedo, PA; Francisco, W; Oliveira, AD | 1 |
| Amyes, SG; Dobay, O; Ghidán, A; Matuz, M; Nagy, K; Rozgonyi, F | 1 |
| Catero, M | 1 |
| Kaatz, GW; LaPlante, KL; Lodise, TP; Rybak, MJ; Tsuji, B | 1 |
| Gidoh, M | 1 |
| Blondeau, JM; Borsos, S; Hesje, CK | 1 |
| De Souza, MV; Junior, IN; Lourenço, MC | 1 |
| Clark, KP; Griffith, ME; Hawley, JS; Hospenthal, DR; Johnson, EN; Moon, JE; Murray, CK | 1 |
| Blondeau, JM; Hedlin, P | 1 |
| Fukushima, K; Higashiyama, Y; Hirakata, Y; Kohno, S; Kohno, Y; Miyazaki, Y; Ohno, H; Yanagihara, K | 1 |
| Holland, EJ; Holland, S; McCarthy, M | 1 |
| Graves, J; Lodise, T; Lomaestro, B; Miller, C; Mohr, JF; Smith, RP | 1 |
| Asari, M; Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Osaka, Y; Yasuda, S | 1 |
| China, A; Dinakaran, M; Nagaraja, V; Senthilkumar, P; Sriram, D; Yogeeswari, P | 1 |
| Boom, WH; Dietze, R; Hadad, DJ; Johnson, JL; Molino, LP; Palaci, M; Peloquin, CA | 1 |
| LaPlante, KL; Mersfelder, TL; Quilliam, BJ; Ward, KE | 1 |
| Bezwada, P; Clark, LA; Schneider, S | 1 |
| Inoue, T; Kida, T; Naka, H; Sakaki, H; Tokushige, H; Wada, T | 1 |
| Allen, J; Coleman, DJ; Davies, GR; Fourie, B; Kanyok, T; Levin, J; Lienhardt, C; Mitchison, DA; Mthiyane, T; Reddy, C; Rustomjee, R; Sirgel, FA; Sturm, AW | 1 |
| Hatou, S; Yamada, M; Yoshida, J | 1 |
| Jacob, JJ; Singh, N | 1 |
| Hatou, S; Minagawa, Y; Yamada, M; Yoshida, J; Yoshida, T | 1 |
| Kozai, S; Ohashi, Y; Sakaki, H; Suzuki, T; Tajika, T; Wada, T | 1 |
| Hiramatsu, K; Hoshi, S; Kikuchi, K; Kinoshita, S; Sasaki, T; Sotozono, C | 1 |
| Mullangi, R; Narasu, L; Shankar, BP; Srinivas, N | 1 |
| Fiscella, RG; Jensen, MK; Mooney, B; Moshirfar, M | 1 |
| Asbell, PA; Epstein, SP; Sosa, AB | 1 |
| Bai, XQ; Deng, SJ; Li, L; Li, R; Liang, QF; Luo, SY; Sun, XG; Wang, ZQ | 1 |
| Scoper, SV | 1 |
| Becnel Boyd, L; Morgan-Linnell, SK; Steffen, D; Zechiedrich, L | 1 |
| Becnel Boyd, L; Hamill, RJ; Horton, LB; Jimenez, JR; Maynard, MJ; Morgan-Linnell, SK; Steffen, D; Sucgang, R; Versalovic, J; Zechiedrich, L | 1 |
| Kobayakawa, S; Tochikubo, T; Tsuchiya, Y; Tsuji, A | 1 |
| Qi, HM; Wei, MJ; Zhang, L; Zhao, CY | 1 |
| Aihara, M; Eguchi, S; Minami, K; Miyanaga, M; Miyata, K; Sawaguchi, S; Shiroma, H | 1 |
| Choi, JS; Joo, CK; Kim, KA; Lim, JA; Park, SH | 1 |
| Baeyens, WR; Fei, G; He, L; Huang, C; Ouyang, J; Wang, Y | 1 |
| Holland, EJ; Lane, SS; Lindstrom, RL | 1 |
| McCulley, JP | 1 |
| Alam, MR; Garg, P; Gopinathan, U; Krishnaiah, S; Reddy, AK; Sharma, S | 1 |
| Hori, Y; Inoue, T; Kubota, A; Maeda, N; Nakazawa, T; Nishida, K; Sakamoto, M; Tano, Y; Yokokura, S | 1 |
| Barbanti, F; Barbut, F; Louie, T; Mastrantonio, P; Spigaglia, P | 1 |
| Kim, J; Ohtani, H; Sawada, Y; Tsujimoto, M | 1 |
| Albert, C; Holzgrabe, U; Waibel, B | 1 |
| Chen, WL; Hu, FR; Tsai, TH | 1 |
| Blondeau, JM; Borsos, SD; Hesje, CK | 1 |
| Choi, JA; Chung, SK | 1 |
| Asari, S; Inoue, Y; Miyai, T; Miyanaga, M; Miyata, K; Nejima, R; Ohashi, Y; Toyokawa, M | 1 |
| Anupama, M; Murthy, PB; Seiler, JP | 1 |
| Chen, WJ; Huang, XD; Yao, K; Yuan, JQ; Zhang, Z | 1 |
| Du, LM; Wu, H; Zhao, GY | 1 |
| Disratthakit, A; Doi, N | 1 |
| Gauhar, S; Iffat, W; Muhammad, IN; Shoaib, MH; Tasleem, S | 1 |
| Cai, HL; Chen, YC; Fang, PF; Gao, W; Li, HD; Liu, YP; Tan, QY; Xu, P; Zhang, F; Zhang, WY; Zhu, RH | 1 |
| Aubry, A; Chauffour, A; Farinotti, R; Fernandez, C; Jarlier, V; Lott, MC; Poissy, J; Veziris, N | 1 |
| Gong, L; Qiu, XD; Qu, J; Sun, XH; Xiong, QC; Yuan, ZL; Zhang, YQ | 1 |
| Kim, SJ; Toma, HS | 1 |
| Ambrose, PG; Bhavnani, SM; Caws, M; Chau, TT; Dung, NT; Farrar, J; Hammel, JP; Hien, TT; Kulawy, R; Mai, PP; Reynolds, DK; Thwaites, GE; Török, ME; Van Wart, SA | 1 |
| Green, K; Low, DE; McGeer, A; Melano, R; Patel, SN; Pillai, DR; Tyrrell, GJ | 1 |
| Dalla Costa, T; de Andrade, C; Tasso, L | 1 |
| Dave, SB; Kim, SJ; Toma, HS | 2 |
| Alekperov, SI; Boĭko, ÉV; Fokina, DV; Reĭtuzov, VA | 1 |
| Menchini, U; Mencucci, R; Paladini, I; Pellegrini-Giampietro, DE; Scartabelli, T | 1 |
| Bugaenko, SE; Elistratova, NA; Maliev, BM; Mozhokina, GN; Sokolova, GB; Solov'eva, IP | 1 |
| Chen, H; Jiang, H; Liu, T; Song, Z; Wu, X; Xu, Y; Yang, L; Yue, W | 1 |
| Galvis, V; Rey, JJ; Tello, A; Villareal, D; Wong, CA | 1 |
| Fukuda, M; Hori, Y; Inatomi, T; Kinoshita, S; Kubota, A; Maeda, N; Nakazawa, T; Nishida, K; Ohashi, Y; Satake, Y; Shimazaki, J; Shimomura, Y; Uno, T; Yamada, M | 1 |
| Chavda, K; Drlica, K; Hussain, S; Kerns, RJ; Kreiswirth, BN; Kurepina, N; Malik, M; Shah, N; Zhao, X | 1 |
| Liu, M; Xia, Q; Yang, Y | 1 |
| Chen, ZJ; Han, L; Sun, ST; Wang, LY; Yue, J; Zhang, YQ | 1 |
| Bukatina, AA; Galkina, KY; Isaeva, YD; Makarova, MV; Moroz, AM; Nosova, EY | 1 |
| Ding, Y; Gu, S; Li, L; Liu, X; Zhang, F | 1 |
| Choi, CY; Kim, HK; Kim, JM; Kim, MS | 1 |
| Bito, M; Kihira, K; Kimura, Y; Komori, M; Taogoshi, T; Tomita, T | 1 |
| Bian, A; Blackman, A; Eden, S; Maruri, F; Mitchel, E; Shintani, AK; Sterling, TR; van der Heijden, YF; Warkentin, JV | 1 |
| Lu, J; Pang, Y; Wang, Y; Zhang, Z; Zhao, Y | 1 |
| Agrawal, K; Arjyal, A; Baker, S; Basnyat, B; Campbell, J; Dolecek, C; Dongol, S; Farrar, J; Giri, A; Karkey, A; Koirala, KD; Koirala, S; Pathak, KR; Shakya, M; Shilpakar, O; Shrestha, K; Shrestha, R; Shrestha, UM; Thapa, SD; Wolbers, M | 1 |
| Antti, H; Arjyal, A; Baker, S; Basnyat, B; Dolecek, C; Dongol, S; Ha Thanh, T; Johansson, A; Karkey, A; Näsström, E; Thwaites, G; Voong Vinh, P; Vu Thieu, NT | 1 |
| Arjyal, A; Baker, S; Basnyat, B; Blacksell, SD; Day, N; Dolecek, C; Dongol, S; Farrar, J; Giri, A; Karkey, A; Paris, DH; Thompson, CN; Thwaites, G | 1 |
| Chaiprasert, A; Disratthakit, A; Doi, N; Leechawengwongs, M; Prammananan, T; Thaipisuttikul, I; Tribuddharat, C | 1 |
| Arjyal, A; Baker, S; Basnyat, B; Darton, T; Dolecek, C; Dongol, S; Farrar, JJ; Karkey, A; Thompson, CN; Thwaites, GE; Wolbers, M | 1 |
| Capparelli, E; Catanzaro, DG; Rodwell, TC; Seifert, M | 1 |
| Das, S; Gunasekaran, R; Mitra, S; Mohamed, A; Prajna, L; Prajna, NV; Sharma, S; Soni, T | 1 |
| Agrawal, D; Chatterjee, S; Gangwe, AB; Gomase, SN; Mishra, M; Parchand, SM | 1 |
| Foroughi, MM; Jahani, S; Moradalizadeh, M; Taherizadeh, M | 1 |
9 review(s) available for ofloxacin and gatifloxacin
| Article | Year |
|---|---|
Fluoroquinolone derivatives and their anti-tubercular activities.
Topics: Animals; Antitubercular Agents; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Tuberculosis | 2018 |
Quinolone antibiotics.
Topics: | 2019 |
An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: A review.
Topics: Animals; Antitubercular Agents; Drug Design; Drug Discovery; Humans; Mycobacterium tuberculosis; Piperazine; Structure-Activity Relationship; Tuberculosis | 2021 |
The expanding role of fluoroquinolones.
Topics: Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Enoxacin; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Norfloxacin; Ofloxacin; Quinolones; Urinary Tract Infections | 2002 |
Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Drug Resistance, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmology; Quinolines | 2004 |
[New fluoroquinolones: levofloxacin, moxifloxacin and gatifloxacin].
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Pneumonia; Quinolines; Respiratory Tract Infections | 2004 |
Current management of acute bacterial rhinosinusitis and the role of moxifloxacin.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Clinical Trials as Topic; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Levofloxacin; Meta-Analysis as Topic; Moxifloxacin; Ofloxacin; Practice Guidelines as Topic; Quinolines; Rhinitis; Sinusitis; Streptococcus pneumoniae | 2005 |
Dysglycemia and fluoroquinolones: are you putting patients at risk?
Topics: Adolescent; Adult; Aza Compounds; Bacterial Infections; Blood Glucose; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Evidence-Based Medicine; Family Practice; Female; Fluoroquinolones; Gatifloxacin; Humans; Hyperglycemia; Hypoglycemia; Incidence; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Randomized Controlled Trials as Topic; Risk Assessment; United States; United States Food and Drug Administration | 2007 |
Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.
Topics: Administration, Topical; Anti-Bacterial Agents; Aza Compounds; Endophthalmitis; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Ophthalmology; Quinolines | 2008 |
17 trial(s) available for ofloxacin and gatifloxacin
| Article | Year |
|---|---|
Single-dose gatifloxacin compared with ofloxacin for the treatment of uncomplicated gonorrhea: a randomized, double-blind, multicenter trial.
Topics: Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Double-Blind Method; Drug Administration Schedule; Female; Fluoroquinolones; Gatifloxacin; Gonorrhea; Humans; Male; Ofloxacin; Treatment Outcome; United States | 2001 |
Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Infective Agents; Double-Blind Method; Drug Administration Schedule; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcus aureus; Treatment Outcome | 2001 |
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Single-Blind Method; Tuberculosis, Pulmonary | 2006 |
The ocular penetration of levofloxacin 1.5% and gatifloxacin 0.3% ophthalmic solutions in subjects undergoing corneal transplant surgery.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Cornea; Corneal Transplantation; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Ophthalmic Solutions | 2007 |
Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Brazil; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Tuberculosis, Pulmonary | 2008 |
A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug Therapy, Combination; Female; Fluoroquinolones; Gatifloxacin; Humans; Isoniazid; Male; Middle Aged; Moxifloxacin; Nonlinear Dynamics; Ofloxacin; Pyrazinamide; Quinolines; Rifampin; Sputum | 2008 |
A comparison of fluoroquinolone penetration into human conjunctival tissue.
Topics: Adult; Aged; Anti-Infective Agents; Aza Compounds; Conjunctiva; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines | 2008 |
Changes in drug susceptibility and the quinolone-resistance determining region of Staphylococcus epidermidis after administration of fluoroquinolones.
Topics: Aged; Aged, 80 and over; Bacterial Proteins; Cataract Extraction; Conjunctiva; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Genes, MDR; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Ophthalmic Solutions; Polymerase Chain Reaction; Prospective Studies; Staphylococcus epidermidis | 2009 |
[Human aqueous humor levels of levofloxacin 0.5%, gatifloxacin 0.3% and levofloxacin 0.3% ophthalmic solution after topical dosing].
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aqueous Humor; Double-Blind Method; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Ophthalmic Solutions | 2009 |
[Comparative research of the efficacy of the gatifloxacin and levofloxacin for bacterial conjunctivitis in human eyes].
Topics: Adolescent; Adult; Conjunctivitis, Bacterial; Double-Blind Method; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Young Adult | 2010 |
Ophthalmic antibiotics and antimicrobial resistance a randomized, controlled study of patients undergoing intravitreal injections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Azithromycin; Conjunctiva; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Intravitreal Injections; Levofloxacin; Middle Aged; Moxifloxacin; Nasopharynx; Ofloxacin; Prospective Studies; Quinolines; Staphylococcal Infections | 2011 |
Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Ciprofloxacin; Ethambutol; Female; Fluoroquinolones; Gatifloxacin; Humans; Injections, Intramuscular; Isoniazid; Levofloxacin; Male; Middle Aged; Multivariate Analysis; Ofloxacin; Pyrazinamide; Rifampin; Streptomycin; Tuberculosis, Meningeal; Young Adult | 2011 |
Ophthalmic antibiotic use and multidrug-resistant staphylococcus epidermidis: a controlled, longitudinal study.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Choroidal Neovascularization; Conjunctiva; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Follow-Up Studies; Gatifloxacin; Humans; Intravitreal Injections; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Prospective Studies; Quinolines; Staphylococcus epidermidis; Young Adult | 2011 |
Comparison of corneal and aqueous humor penetration of moxifloxacin, gatifloxacin and levofloxacin during keratoplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Biological Availability; Cornea; Female; Fluoroquinolones; Gatifloxacin; Humans; Keratoplasty, Penetrating; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines | 2012 |
Changes in ocular flora in eyes exposed to ophthalmic antibiotics.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Bacteria; Choroidal Neovascularization; Conjunctiva; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Intravitreal Injections; Longitudinal Studies; Moxifloxacin; Ofloxacin; Quinolines | 2013 |
Gatifloxacin versus ofloxacin for the treatment of uncomplicated enteric fever in Nepal: an open-label, randomized, controlled trial.
Topics: Adolescent; Anti-Bacterial Agents; Child; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Nepal; Ofloxacin; Salmonella paratyphi A; Salmonella typhi; Treatment Failure; Typhoid Fever; Young Adult | 2013 |
Treatment Response in Enteric Fever in an Era of Increasing Antimicrobial Resistance: An Individual Patient Data Analysis of 2092 Participants Enrolled into 4 Randomized, Controlled Trials in Nepal.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Child; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Microbial Sensitivity Tests; Nepal; Ofloxacin; Paratyphoid Fever; Salmonella paratyphi A; Salmonella typhi; Treatment Failure; Treatment Outcome; Typhoid Fever; Young Adult | 2017 |
189 other study(ies) available for ofloxacin and gatifloxacin
| Article | Year |
|---|---|
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
Topics: Anti-Infective Agents; DNA; DNA Gyrase; DNA, Superhelical; Enzyme Inhibitors; Mycobacterium leprae; Quinolones; Topoisomerase II Inhibitors | 2007 |
Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones.
Topics: Anti-Bacterial Agents; Asia; Bangladesh; China; DNA Gyrase; DNA Mutational Analysis; DNA Topoisomerase IV; Drug Resistance, Microbial; Fluoroquinolones; Humans; India; Indonesia; Laos; Microbial Sensitivity Tests; Mutation; Nepal; Pakistan; Salmonella typhi; Vietnam | 2007 |
Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
Topics: Alleles; Amino Acid Sequence; Argentina; Bacterial Proteins; Base Sequence; beta-Lactamases; Cross Infection; DNA Transposable Elements; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Polymerase Chain Reaction; Sequence Analysis, DNA; Sequence Homology, Nucleic Acid | 2007 |
Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
Topics: Anti-Infective Agents; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Mycobacterium leprae | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
Topics: Aged; Base Sequence; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Female; Fluoroquinolones; France; Genes, Bacterial; Humans; Models, Genetic; Molecular Sequence Data; Plasmids | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Interaction of drug based binuclear mixed-ligand complexes with DNA.
Topics: Anti-Bacterial Agents; Bacteria; Binding Sites; Ciprofloxacin; Cobalt; DNA, Bacterial; Ligands; Magnetic Resonance Spectroscopy; Magnetics; Mass Spectrometry; Microbial Sensitivity Tests; Molecular Structure; Oxidation-Reduction; Spectrophotometry, Infrared; Structure-Activity Relationship; Temperature; Viscosity | 2009 |
Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
Topics: Anti-Bacterial Agents; Aza Compounds; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Quinolines | 2009 |
SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Gene Expression Regulation, Bacterial; Microbial Sensitivity Tests; Mutation; Plasmids; Quinolones; Reverse Transcriptase Polymerase Chain Reaction; Stenotrophomonas maltophilia | 2010 |
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
Topics: Caco-2 Cells; Cell Membrane Permeability; Humans; Hydrogen-Ion Concentration; Membranes, Artificial; Molecular Structure; Pharmaceutical Preparations | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Aza Compounds; DNA Cleavage; DNA Gyrase; Fluoroquinolones; Gatifloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium leprae; Mycobacterium tuberculosis; Quinolines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2013 |
The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
Topics: Anti-Bacterial Agents; Binding Sites; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Humans; Models, Molecular; Potassium Channel Blockers; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Piperidines; Respiratory Tract Infections; Staphylococcal Infections; Staphylococcus; Streptococcus pneumoniae; Structure-Activity Relationship | 2022 |
In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; DNA Topoisomerases, Type II; Drug Evaluation, Preclinical; Fluoroquinolones; Gatifloxacin; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Piperazines; Quinolones; Tissue Distribution | 1992 |
Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin.
Topics: Animals; Anti-Infective Agents; Female; Fluoroquinolones; Gatifloxacin; Intracellular Fluid; Macrophages; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium chelonae; Mycobacterium tuberculosis; Nontuberculous Mycobacteria; Ofloxacin; Piperazines; Quinolones | 1993 |
Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus | 1997 |
Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
Topics: Amoxicillin; Anti-Infective Agents; Ceftriaxone; Cefuroxime; Cephalosporins; Ciprofloxacin; Clarithromycin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Penicillin Resistance; Streptococcus pneumoniae | 1999 |
Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterat
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Enterobacter cloacae; Fluoroquinolones; Gatifloxacin; Humans; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Molecular Sequence Data; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 1999 |
Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Topics: Anti-Infective Agents; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium tuberculosis; Ofloxacin; Quinolones | 1999 |
Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.
Topics: Anti-Infective Agents; Blood Coagulation; Ciprofloxacin; Fibrin; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Penicillin Resistance; Pneumococcal Infections; Streptococcus pneumoniae | 2000 |
Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines | 2000 |
Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains.
Topics: Acinetobacter; Acinetobacter Infections; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Outbreaks; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Germany; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2000 |
Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Streptococcus pneumoniae | 2000 |
In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Escherichia coli; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Klebsiella; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Urinary Tract Infections | 2000 |
The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Area Under Curve; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Monte Carlo Method; Ofloxacin; Pneumococcal Infections; Streptococcus pneumoniae | 2000 |
Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).
Topics: Anti-Infective Agents; Ciprofloxacin; Databases, Factual; Enterobacteriaceae; Fluoroquinolones; Gatifloxacin; Gram-Positive Cocci; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Predictive Value of Tests; Pseudomonas aeruginosa | 2001 |
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
Topics: Anti-Infective Agents; Aza Compounds; Canada; Ciprofloxacin; Europe; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Indoles; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; United States | 2001 |
Activity of gatifloxacin against strains resistant to ofloxacin and ciprofloxacin and its ability to select for less susceptible bacterial variants.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Escherichia coli; Fluoroquinolones; Gatifloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Mutation; Neisseria gonorrhoeae; Ofloxacin; Staphylococcus aureus; Streptococcus pneumoniae | 2001 |
In vitro activity of fluoroquinolones (gatifloxacin, levofloxacin and trovafloxacin) and seven other antibiotics against Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Gatifloxacin; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Pneumococcal Infections; Streptococcus pneumoniae | 2001 |
Propensity of fluoroquinolones with different moieties at position 8 to cause resistance development in clinical isolates of Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Streptococcus pneumoniae | 2001 |
Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different!
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Drug Resistance, Bacterial; Europe; Fluoroquinolones; Gatifloxacin; Humans; Lactams; Latin America; Levofloxacin; Microbial Sensitivity Tests; North America; Ofloxacin; Population Surveillance; Pseudomonas aeruginosa; Pseudomonas Infections; Regional Medical Programs; Urinary Tract Infections | 2001 |
Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae.
Topics: Adolescent; Adult; Anti-Infective Agents; Area Under Curve; Community-Acquired Infections; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Models, Statistical; Monte Carlo Method; Ofloxacin; Predictive Value of Tests; Streptococcus pneumoniae | 2001 |
Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Electrocardiography; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies; Torsades de Pointes | 2001 |
[Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii].
Topics: Acinetobacter; Acinetobacter Infections; Ampicillin; Anti-Infective Agents; Aza Compounds; Cefepime; Cephalosporins; Ciprofloxacin; Colistin; Fluoroquinolones; Gatifloxacin; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Moxifloxacin; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Opportunistic Infections; Quinolines; Sulbactam; Thienamycins | 2001 |
Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Drug Resistance, Microbial; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies | 2002 |
Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ceftriaxone; Child; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Penicillin Resistance; Penicillins; Pneumococcal Infections; Streptococcus pneumoniae; United States | 2002 |
Single and multi-step resistance selection study in Streptococcus pneumoniae comparing ceftriaxone with levofloxacin, gatifloxacin and moxifloxacin.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ceftriaxone; Culture Media; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Selection, Genetic; Streptococcus pneumoniae | 2002 |
In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.
Topics: Acetamides; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Linezolid; Male; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Oxazolidinones; Quinolines; Tuberculosis | 2002 |
Bactericidal activity of levofloxacin, gatifloxacin, penicillin, meropenem and rokitamycin against Bacillus anthracis clinical isolates.
Topics: Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Bacillus anthracis; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Miocamycin; Ofloxacin; Penicillins; Thienamycins | 2002 |
In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Haemophilus influenzae; Korea; Levofloxacin; Microbial Sensitivity Tests; Moraxella; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2002 |
Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team.
Topics: Anti-Infective Agents; Area Under Curve; Drug Resistance, Bacterial; Epidemiologic Methods; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Streptococcus pneumoniae | 2003 |
[In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dosage Forms; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fleroxacin; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines; Prodrugs; Quinolones | 2002 |
[In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Gatifloxacin; Levofloxacin; Ofloxacin; Piperazines; Prodrugs; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus; Time Factors | 2002 |
[Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Cefdinir; Cephalosporins; Ciprofloxacin; Dosage Forms; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Macrolides; Ofloxacin; Otorhinolaryngologic Diseases; Respiratory Tract Infections; Staphylococcus aureus; Streptococcus pneumoniae; Time Factors; Urinary Tract Infections | 2002 |
[Inhibitory activity of NM394, the active form of prodrug prulifloxacin against type II topoisomerase from Pseudomonas aeruginosa].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Fluoroquinolones; Gatifloxacin; Levofloxacin; Ofloxacin; Piperazines; Prodrugs; Pseudomonas aeruginosa; Quinolones; Topoisomerase II Inhibitors | 2002 |
[Pneumococcus and quinolone resistance].
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Child, Preschool; Ciprofloxacin; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Humans; Male; Microbial Sensitivity Tests; Moxifloxacin; Multivariate Analysis; Mutation; Ofloxacin; Penicillin Resistance; Penicillins; Pneumococcal Infections; Pneumonia, Pneumococcal; Quinolines; Recurrence; Risk Factors; Streptococcus pneumoniae | 2003 |
In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Ofloxacin; Oxazolidinones; Quinolines; Spain | 2003 |
In vitro and in vivo activities of fluoroquinolones against Aeromonas hydrophila.
Topics: Aeromonas hydrophila; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Cefotaxime; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacterial Infections; Humans; In Vitro Techniques; Levofloxacin; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Ofloxacin; Quinolines; Quinolones | 2003 |
Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae.
Topics: Anti-Infective Agents; Aza Compounds; Chlamydophila pneumoniae; DNA Gyrase; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Indoles; Levofloxacin; Molecular Sequence Data; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Topoisomerase II Inhibitors | 2003 |
Fluoroquinolone therapy in multiple-drug resistant staphylococcal keratitis after lamellar keratectomy in a rabbit model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Keratitis; Keratomileusis, Laser In Situ; Levofloxacin; Ofloxacin; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Surgical Flaps | 2003 |
Antimicrobial susceptibilities of 40 isolates of Bacillus anthracis isolated in Turkey.
Topics: Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Ciprofloxacin; Doxycycline; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Penicillin G; Penicillins; Turkey | 2003 |
Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines.
Topics: Anti-Infective Agents; Antibiotics, Antitubercular; Cell Line; Epithelial Cells; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Macrophages; Mycobacterium tuberculosis; Ofloxacin; Pulmonary Alveoli | 2003 |
A novel method of estimating cost of therapy by using patient population characteristics: analysis of fluoroquinolones in various populations with different distributions of renal function.
Topics: Administration, Oral; Anti-Bacterial Agents; Aza Compounds; Costs and Cost Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoroquinolones; Formularies, Hospital as Topic; Gatifloxacin; Humans; Infusions, Intravenous; Kidney; Kidney Function Tests; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
Accumulation of garenoxacin by Bacteroides fragilis compared with that of five fluoroquinolones.
Topics: Aza Compounds; Bacteroides fragilis; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Membrane Transport Modulators; Membrane Transport Proteins; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Corneal Ulcer; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
The effect of pharmacokinetic/pharmacodynamic (PK/PD) parameters of gatifloxacin on its bactericidal activity and resistance selectivity against clinical isolates of Streptococcus pneumoniae.
Topics: Administration, Oral; Area Under Curve; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Theoretical; Ofloxacin; Streptococcus pneumoniae | 2003 |
[Comparative in vitro activity of garenoxacin (BMS-284756). Sentry program, Spain (1999-2000)].
Topics: Anti-Infective Agents; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Species Specificity; Staphylococcus aureus; Streptococcus pneumoniae | 2003 |
Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones.
Topics: Aza Compounds; Bacteroides fragilis; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2003 |
In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV.
Topics: Analysis of Variance; Aza Compounds; Culture Media; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Pharmacogenetics; Pneumococcal Infections; Probability; Quinolines; Reference Values; Regression Analysis; Sensitivity and Specificity; Streptococcus pneumoniae | 2003 |
[Analysis of the response factors of different quinolones detected by evaporative light-scattering detector].
Topics: Chromatography, High Pressure Liquid; Ciprofloxacin; Enoxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Light; Linear Models; Ofloxacin; Quinolones | 2003 |
Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use.
Topics: Case-Control Studies; Clostridioides difficile; Clostridium Infections; Cross Infection; Diarrhea; Disease Outbreaks; Drug Resistance, Bacterial; Fluoroquinolones; Follow-Up Studies; Gatifloxacin; Humans; Levofloxacin; Long-Term Care; Microbial Sensitivity Tests; Ofloxacin | 2004 |
Mutations in the gyrA and parC genes and in vitro activities of fluoroquinolones in 91 clinical isolates of Neisseria gonorrhoeae in Japan.
Topics: Anti-Infective Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gonorrhea; Humans; Japan; Levofloxacin; Male; Microbial Sensitivity Tests; Mutation; Neisseria gonorrhoeae; Ofloxacin | 2004 |
Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections.
Topics: Abdominal Injuries; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Bacteria, Aerobic; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Respiratory Tract Infections; Wound Infection | 2004 |
Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients.
Topics: Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Doxycycline; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Hospitalization; Humans; Levofloxacin; Macrolides; Moxifloxacin; Naphthyridines; Ofloxacin; Outcome Assessment, Health Care; Pneumonia, Bacterial; Quinolines; Retrospective Studies | 2004 |
Effects of fluoroquinolones on the migration of human phagocytes through Chlamydia pneumoniae-infected and tumor necrosis factor alpha-stimulated endothelial cells.
Topics: Anti-Infective Agents; Aza Compounds; Cell Movement; Chemokines; Chlamydia; Endothelial Cells; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Monocytes; Moxifloxacin; Neutrophils; Ofloxacin; Phagocytes; Pneumonia, Bacterial; Quinolines; Stimulation, Chemical; Tumor Necrosis Factor-alpha; Umbilical Veins | 2004 |
Aqueous penetration of gatifloxacin and levofloxacin into the rabbit aqueous humor following topical dosing.
Topics: Animals; Anti-Bacterial Agents; Aqueous Humor; Biological Availability; Chromatography, High Pressure Liquid; Fluoroquinolones; Gatifloxacin; Instillation, Drug; Levofloxacin; Male; Microbial Sensitivity Tests; Ofloxacin; Rabbits; Reference Standards | 2004 |
Pharmacodynamics and bactericidal activity of gatifloxacin in experimental pneumonia caused by penicillin-resistant Streptococcus pneumoniae.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Evaluation, Preclinical; Fluoroquinolones; Gatifloxacin; Levofloxacin; Lung; Mice; Mice, Inbred CBA; Ofloxacin; Penicillin Resistance; Pneumonia, Pneumococcal; Survival Rate | 2004 |
Urinary concentrations and bactericidal activities of newer fluoroquinolones in healthy volunteers.
Topics: Adult; Anti-Infective Agents; Aza Compounds; Enterobacteriaceae; Enterococcus faecalis; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2004 |
Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels.
Topics: Adenosine Triphosphate; Animals; Anti-Bacterial Agents; Cells, Cultured; Fluoroquinolones; Gatifloxacin; Insulin; Insulin Secretion; Islets of Langerhans; Levofloxacin; Mice; Ofloxacin; Patch-Clamp Techniques; Potassium Channels; Quinolones | 2004 |
Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics.
Topics: Anti-Bacterial Agents; Aza Compounds; DNA Topoisomerases, Type II; DNA, Bacterial; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Monte Carlo Method; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; Streptococcus pneumoniae | 2004 |
The incidence of Clostridium difficile-associated and non-C. difficile-associated diarrhea after use of gatifloxacin and levofloxacin in an acute-care facility.
Topics: Clostridioides difficile; Clostridium Infections; Diarrhea; Emergency Medical Services; Fluoroquinolones; Gatifloxacin; Humans; Incidence; Levofloxacin; Ofloxacin | 2004 |
Simultaneous determination of levofloxacin, gatifloxacin and moxifloxacin in serum by liquid chromatography with column switching.
Topics: Anti-Infective Agents; Aza Compounds; Calibration; Chromatography, High Pressure Liquid; Fluoroquinolones; Gatifloxacin; Humans; Hydrogen-Ion Concentration; Levofloxacin; Moxifloxacin; Ofloxacin; Quality Control; Quinolines; Reference Standards; Reproducibility of Results | 2004 |
Action of fluoroquinolones and Linezolid on logarithmic- and stationary-phase culture of Mycobacterium tuberculosis.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Culture Media; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Hydrogen-Ion Concentration; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Oxazolidinones; Quinolines; Rifampin; Structure-Activity Relationship; Time Factors | 2004 |
Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Ciprofloxacin; Drug Resistance, Bacterial; Ertapenem; Escherichia coli; Fluoroquinolones; Gatifloxacin; Humans; Imipenem; Klebsiella pneumoniae; Lactams; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Ofloxacin; Thienamycins | 2004 |
Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Quinolones; Respiratory Tract Infections; Streptococcus pneumoniae | 2005 |
[Antimicrobial susceptibility surveillance of recent isolates from ophthalmological infections to gatifloxacin and other antimicrobial drugs].
Topics: Anti-Infective Agents; Drug Resistance, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Humans; Levofloxacin; Ofloxacin; Quinolones | 2005 |
Effects of fluoroquinolones on the migration of human phagocytes through Chlamydia pneumoniae-infected and tumor necrosis factor alpha-stimulated endothelial cells.
Topics: Aza Compounds; Cell Line; Cell Movement; Chemokine CCL2; Chlamydia Infections; Chlamydophila pneumoniae; Endothelium, Vascular; Fluoroquinolones; Gatifloxacin; Humans; Interleukin-8; Monocytes; Moxifloxacin; Neutrophils; Ofloxacin; Phagocytosis; Quinolines; Stimulation, Chemical; Tumor Necrosis Factor-alpha | 2005 |
In vitro activity of fluoroquinolones against Mycobacterium tuberculosis.
Topics: Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Quinolones; Sampling Studies; Sensitivity and Specificity | 2005 |
Antibacterial activities of gemifloxacin, levofloxacin, gatifloxacin, moxifloxacin and erythromycin against intracellular Legionella pneumophila and Legionella micdadei in human monocytes.
Topics: Anti-Bacterial Agents; Aza Compounds; Dose-Response Relationship, Drug; Erythromycin; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Legionella; Legionella pneumophila; Levofloxacin; Microbial Sensitivity Tests; Monocytes; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2005 |
Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae.
Topics: Adult; Aged; Community-Acquired Infections; Drug Administration Schedule; Epidemiologic Methods; Fluoroquinolones; Gatifloxacin; Hospitalization; Humans; Levofloxacin; Middle Aged; Monte Carlo Method; Ofloxacin; Pneumococcal Infections; Predictive Value of Tests; Streptococcus pneumoniae | 2005 |
Quantitative determination of gatifloxacin, levofloxacin, lomefloxacin and pefloxacin fluoroquinolonic antibiotics in pharmaceutical preparations by high-performance liquid chromatography.
Topics: Anti-Bacterial Agents; Calibration; Chemistry Techniques, Analytical; Chemistry, Pharmaceutical; Chromatography; Chromatography, High Pressure Liquid; Ethylamines; Fluoroquinolones; Gatifloxacin; Hydrogen-Ion Concentration; Levofloxacin; Models, Chemical; Models, Statistical; Ofloxacin; Pefloxacin; Pharmaceutical Preparations; Quinolones; Regression Analysis; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Tablets; Temperature; Time Factors | 2006 |
Fluoroquinolone therapy in Mycobacterium chelonae keratitis after lamellar keratectomy.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Corneal Transplantation; Disease Models, Animal; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Keratitis; Levofloxacin; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Ofloxacin; Rabbits | 2005 |
Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue.
Topics: Anti-Bacterial Agents; Aza Compounds; Biopsy; Ciprofloxacin; Conjunctiva; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Tissue Distribution | 2005 |
Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
Topics: Anti-Bacterial Agents; Area Under Curve; Ceftriaxone; Computer Simulation; Databases, Factual; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Injections, Intravenous; Levofloxacin; Microbial Sensitivity Tests; Monte Carlo Method; Ofloxacin; Streptococcus pneumoniae | 2005 |
Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Blood Glucose; Case-Control Studies; Female; Fluoroquinolones; Gatifloxacin; Humans; Hypoglycemia; Levofloxacin; Male; Middle Aged; Ofloxacin; Risk Factors | 2005 |
A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Blood Glucose; Ceftriaxone; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Humans; Hyperglycemia; Hypoglycemia; Levofloxacin; Male; Middle Aged; Ofloxacin; Product Surveillance, Postmarketing; Retrospective Studies | 2005 |
Glucose homeostasis abnormalities associated with use of gatifloxacin.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Child; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Glucose; Homeostasis; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines | 2005 |
Pharmacodynamic assessment of the activity of high-dose (750 mg) levofloxacin, ciprofloxacin, and gatifloxacin against clinical strains of Pseudomonas aeruginosa.
Topics: Anti-Infective Agents; Area Under Curve; Ciprofloxacin; DNA, Bacterial; Evaluation Studies as Topic; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa | 2006 |
Effects of Transcutol P on the corneal permeability of drugs and evaluation of its ocular irritation of rabbit eyes.
Topics: 1-Octanol; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Cornea; Drug Carriers; Enoxacin; Ethylene Glycols; Eye; Fluoroquinolones; Gatifloxacin; In Vitro Techniques; Irritants; Levofloxacin; Ofloxacin; Oxaprozin; Permeability; Propionates; Rabbits; Ribavirin; Water | 2006 |
Efficacy of quinolones against secondary pneumococcal pneumonia after influenza virus infection in mice.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Lung; Mice; Mice, Inbred BALB C; Ofloxacin; Orthomyxoviridae Infections; Pneumonia, Pneumococcal | 2006 |
Comparative study of antimicrobial release kinetics from polymethylmethacrylate.
Topics: Acetamides; Anti-Bacterial Agents; Area Under Curve; Cefazolin; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Linezolid; Ofloxacin; Oxazolidinones; Polymethyl Methacrylate; Rifampin | 2006 |
Glucose homeostasis abnormalities and gatifloxacin.
Topics: Aza Compounds; Fluoroquinolones; Gatifloxacin; Glucose; Homeostasis; Humans; Hyperglycemia; Hypoglycemia; Moxifloxacin; Ofloxacin; Quinolines | 2006 |
Vibrational spectra study on quinolones antibiotics.
Topics: Anti-Bacterial Agents; Fluoroquinolones; Gatifloxacin; Molecular Structure; Ofloxacin; Quinolones; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Vibration | 2006 |
Outpatient gatifloxacin therapy and dysglycemia in older adults.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Anti-Bacterial Agents; Case-Control Studies; Cephalosporins; Diabetes Complications; Female; Fluoroquinolones; Gatifloxacin; Hospitalization; Humans; Hyperglycemia; Hypoglycemia; Levofloxacin; Macrolides; Male; Ofloxacin; Ontario; Risk | 2006 |
Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Cefuroxime; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Genes, Bacterial; Levofloxacin; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Escherichia coli; Fluoroquinolones; Formularies as Topic; Gatifloxacin; Gram-Negative Bacteria; Humans; Levofloxacin; Methicillin; Methicillin Resistance; Ofloxacin; Pseudomonas aeruginosa; Regression Analysis; Retrospective Studies; Staphylococcus aureus | 2006 |
In vitro activities of DX-619 and comparison quinolones against gram-positive cocci.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Enterococcus; Fluoroquinolones; Gatifloxacin; Gram-Positive Cocci; In Vitro Techniques; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pyrrolidines; Quinolines; Quinolones; Staphylococcus aureus; Streptococcus pneumoniae; Streptococcus pyogenes | 2006 |
Effectiveness of flouroquinolone therapy for gram-negative infections within the intensive care unit setting.
Topics: Acinetobacter; Alabama; Ciprofloxacin; Drug Resistance, Bacterial; Enterobacter cloacae; Escherichia coli; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals, Community; Humans; Intensive Care Units; Klebsiella oxytoca; Microbial Sensitivity Tests; Ofloxacin; Proteus mirabilis; Pseudomonas aeruginosa; Retrospective Studies | 2006 |
In vitro activity of fluoroquinolones against common respiratory pathogens.
Topics: Aza Compounds; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
Chiral separation of four fluoroquinolone compounds using capillary electrophoresis with hydroxypropyl-beta-cyclodextrin as chiral selector.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; beta-Cyclodextrins; Electrophoresis, Capillary; Fluoroquinolones; Gatifloxacin; Hydrogen-Ion Concentration; Molecular Structure; Ofloxacin; Oxazines; Quinolones; Stereoisomerism | 2006 |
Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease?
Topics: Aged; Aged, 80 and over; Aza Compounds; Case-Control Studies; Clostridioides difficile; Enterocolitis, Pseudomembranous; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines | 2006 |
Fluoroquinolone resistance in Salmonella typhi and S. paratyphi A in Bangalore, India.
Topics: Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Salmonella paratyphi A; Salmonella typhi | 2007 |
Susceptibility testing of clinical isolates of pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating pseudomonas ocular infections.
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines | 2006 |
Anticoagulation-related outcomes in patients receiving warfarin after starting levofloxacin or gatifloxacin.
Topics: Aged; Anticoagulants; Databases as Topic; Drug Monitoring; Drug Therapy, Combination; Female; Fluoroquinolones; Gatifloxacin; Hospitals, Veterans; Humans; International Normalized Ratio; Levofloxacin; Male; Ofloxacin; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome; United States; Warfarin | 2006 |
Prevalence and natural history of colonization with fluoroquinolone-resistant gram-negative bacilli in community-dwelling people with spinal cord dysfunction.
Topics: Anti-Bacterial Agents; Carrier State; Cross-Sectional Studies; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Gram-Negative Aerobic Bacteria; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Perineum; Prevalence; Prospective Studies; Spinal Cord Diseases; Urinary Catheterization; Urinary Incontinence; Urinary Tract Infections | 2006 |
Application of two methods to determine killing of Streptococcus pneumoniae by various fluoroquinolones.
Topics: Anti-Bacterial Agents; Aza Compounds; Cells, Cultured; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
In vitro development of resistance to DX-619 and other quinolones in enterococci.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Enterococcus faecalis; Enterococcus faecium; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Polymerase Chain Reaction; Pyrrolidines; Quinolines; Quinolones; Sequence Analysis, DNA | 2006 |
Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aza Compounds; Bacterial Proteins; Canada; Child; Child, Preschool; Ciprofloxacin; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Genotype; Humans; Infant; Infant, Newborn; Levofloxacin; Middle Aged; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Quinolines; Serotyping; Streptococcus pneumoniae | 2007 |
Evaluation of the penetration of fluoroquinolones in human conjunctival tissue.
Topics: Anti-Bacterial Agents; Aza Compounds; Biopsy; Ciprofloxacin; Conjunctiva; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Tissue Distribution | 2006 |
Biofilm formation on hydrophilic intraocular lens material.
Topics: Acrylic Resins; Animals; Bacterial Adhesion; Biofilms; Colony Count, Microbial; Drug Carriers; Enterococcus faecalis; Fluoroquinolones; Gatifloxacin; Hydrogel, Polyethylene Glycol Dimethacrylate; Lenses, Intraocular; Levofloxacin; Microscopy, Electron, Scanning; Ofloxacin; Polymethyl Methacrylate; Rabbits; Staphylococcus epidermidis | 2006 |
[Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutagenicity Tests; Mutation; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines | 2006 |
Fluoroquinolone resistance among Salmonella enterica serovar Paratyphi A in Pondicherry.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Microbial Sensitivity Tests; Ofloxacin; Salmonella paratyphi A | 2006 |
In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Brazil; Ciprofloxacin; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Incidence; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2007 |
The first steps towards fluoroquinolone resistance in Hungarian pneumococci.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Hungary; Microbial Sensitivity Tests; Moxifloxacin; Mutation, Missense; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 2006 |
Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
Topics: Area Under Curve; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 2007 |
[In-vitro and in-vivo activities of moxifloxacin and garenoxacin against Mycobacterium leprae].
Topics: Animals; Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Leprostatic Agents; Levofloxacin; Mice; Mice, Inbred BALB C; Mice, Nude; Moxifloxacin; Mycobacterium leprae; Ofloxacin; Quinolines; Rifampin | 2007 |
Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus.
Topics: Anti-Infective Agents; Aza Compounds; Benzalkonium Compounds; Cells, Cultured; Ciprofloxacin; Drug Combinations; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Preservatives, Pharmaceutical; Quinolines; Staphylococcus aureus | 2007 |
In vitro activity of ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and gatifloxacin against multidrug-resistant Mycobacterium tuberculosis in Rio de Janeiro Brazil.
Topics: AIDS-Related Opportunistic Infections; Brazil; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Tuberculosis | 2007 |
Efficacy of fluoroquinolones against Leptospira interrogans in a hamster model.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Ciprofloxacin; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Doxycycline; Female; Fluoroquinolones; Gatifloxacin; Injections, Intraperitoneal; Leptospira interrogans; Leptospirosis; Levofloxacin; Mesocricetus; Ofloxacin; Serotyping; Survival Analysis | 2007 |
Comparative minimal inhibitory and mutant prevention drug concentrations of four fluoroquinolones against ocular isolates of Haemophilus influenzae.
Topics: Anti-Infective Agents; Antimutagenic Agents; Aza Compounds; Ciprofloxacin; Dose-Response Relationship, Drug; Eye; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Osmolar Concentration; Quinolines | 2007 |
In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
Topics: Animals; Aza Compounds; Clarithromycin; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Humans; Japan; Levofloxacin; Liver; Lung; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Ofloxacin; Quinolines; Spleen | 2007 |
Effects of gatifloxacin and levofloxacin on rates of hypoglycemia and hyperglycemia among elderly hospitalized patients.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Cohort Studies; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Gatifloxacin; Hospitals, Veterans; Humans; Hyperglycemia; Hypoglycemia; Kidney Diseases; Levofloxacin; Logistic Models; Male; Medication Errors; Ofloxacin; Retrospective Studies | 2007 |
The inhibitory effects of fluoroquinolones on L-carnitine transport in placental cell line BeWo.
Topics: Biological Transport; Carnitine; Cell Line, Tumor; Ciprofloxacin; Drug Interactions; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Ofloxacin; Organic Cation Transport Proteins; Piperazines; Placenta; Sodium; Solute Carrier Family 22 Member 5 | 2008 |
Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation.
Topics: Animals; Antitubercular Agents; Combinatorial Chemistry Techniques; DNA Gyrase; Enzyme Inhibitors; Fluoroquinolones; Gatifloxacin; Lung; Mice; Molecular Structure; Mycobacterium tuberculosis; Ofloxacin; Spleen; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2008 |
Prevalence of and risk factors for dysglycemia in patients receiving gatifloxacin and levofloxacin in an outpatient setting.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Creatinine; Diabetes Complications; Female; Fluoroquinolones; Gatifloxacin; Hospitals, Veterans; Humans; Hyperglycemia; Hypoglycemia; Levofloxacin; Male; Medical Records; Middle Aged; Multivariate Analysis; Ofloxacin; Prevalence; Retrospective Studies; Rhode Island; Risk Factors | 2008 |
Intrinsic cytotoxic effects of fluoroquinolones on human corneal keratocytes and endothelial cells.
Topics: Anti-Bacterial Agents; Aza Compounds; Biological Assay; Ciprofloxacin; Cornea; Corneal Stroma; Endothelial Cells; Endothelium, Corneal; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines | 2008 |
Immunomodulatory effect of gatifloxacin on mouse peritoneal macrophages in vitro and in models of endotoxin-induced rat conjunctivitis and rabbit bacterial keratitis.
Topics: Animals; Anti-Inflammatory Agents; Aza Compounds; Cells, Cultured; Conjunctivitis; Endotoxins; Fluoroquinolones; Gatifloxacin; Immunologic Factors; Keratitis; Levofloxacin; Lipopolysaccharides; Macrophages, Peritoneal; Male; Methicillin Resistance; Mice; Mice, Inbred C3H; Moxifloxacin; Ofloxacin; Quinolines; Rabbits; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Tumor Necrosis Factor-alpha | 2008 |
In vitro susceptibilities of bacterial isolates from conjunctival flora to gatifloxacin, levofloxacin, tosufloxacin, and moxifloxacin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Bacteria; Child; Conjunctiva; Drug Resistance, Microbial; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2008 |
Levofloxacin and hypoglycemia.
Topics: Clinical Competence; Fluoroquinolones; Gatifloxacin; Health Services Research; Hospitals, University; Humans; Hypoglycemia; Levofloxacin; Ofloxacin; Surveys and Questionnaires | 2008 |
Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones.
Topics: Aza Compounds; Conjunctiva; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Genes, MDR; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Staphylococcus epidermidis | 2008 |
Prophylactic efficacy of ophthalmic quinolones in experimental endophthalmitis in rabbits.
Topics: Animals; Anterior Chamber; Anti-Bacterial Agents; Biological Availability; Disease Progression; Endophthalmitis; Enterococcus faecalis; Eye; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacterial Infections; Male; Ofloxacin; Ointments; Ophthalmic Solutions; Quinolones; Rabbits | 2008 |
Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu
Topics: Administration, Topical; Anti-Bacterial Agents; Drug Administration Routes; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Ofloxacin; Ophthalmic Solutions; Staphylococcus aureus | 2008 |
Development and validation of a HPLC method for simultaneous quantitation of gatifloxacin, sparfloxacin and moxifloxacin using levofloxacin as internal standard in human plasma: application to a clinical pharmacokinetic study.
Topics: Administration, Oral; Analytic Sample Preparation Methods; Aza Compounds; Chromatography, High Pressure Liquid; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines; Reference Standards; Sensitivity and Specificity | 2008 |
Third- and fourth-generation fluoroquinolones: retrospective comparison of endophthalmitis after cataract surgery performed over 10 years.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Ciprofloxacin; Cross-Sectional Studies; Endophthalmitis; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Middle Aged; Moxifloxacin; Ofloxacin; Phacoemulsification; Postoperative Complications; Prevalence; Quinolines; Retrospective Studies | 2008 |
Evaluation of toxicity of commercial ophthalmic fluoroquinolone antibiotics as assessed on immortalized corneal and conjunctival epithelial cells.
Topics: Anti-Infective Agents; Aza Compounds; Cell Line; Cell Survival; Ciprofloxacin; Conjunctiva; Drug Evaluation, Preclinical; Epithelial Cells; Epithelium, Corneal; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Tetrazolium Salts; Thiazoles | 2008 |
[Analysis on susceptibility of ocular bacterial pathogens to four kinds of fluoroquinolone].
Topics: Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Eye; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin | 2008 |
Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates.
Topics: Anti-Bacterial Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Escherichia coli; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Norfloxacin; Ofloxacin | 2009 |
Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.
Topics: Ciprofloxacin; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; United States | 2009 |
Preventive effect against post-cataract endophthalmitis: drug delivery intraocular lens versus intracameral antibiotics.
Topics: Animals; Anterior Chamber; Anti-Bacterial Agents; Aqueous Humor; Biological Availability; Cataract Extraction; Chromatography, High Pressure Liquid; Colony Count, Microbial; Drug Delivery Systems; Endophthalmitis; Enterococcus faecalis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacterial Infections; Lens Implantation, Intraocular; Lenses, Intraocular; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Postoperative Complications; Rabbits | 2008 |
Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes.
Topics: Animals; Anti-Infective Agents; Aryl Hydrocarbon Hydroxylases; Aza Compounds; Ciprofloxacin; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9; Fluoroquinolones; Gatifloxacin; Humans; Isoenzymes; Levofloxacin; Microsomes, Liver; Molecular Structure; Moxifloxacin; Ofloxacin; Quinolines; Reproducibility of Results | 2008 |
The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone antibiotics.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Bacteria, Aerobic; Ciprofloxacin; Conjunctiva; Eye; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2009 |
Enhanced separation of seven quinolones by capillary electrophoresis with silica nanoparticles as additive.
Topics: Buffers; Electrophoresis, Capillary; Fleroxacin; Fluoroquinolones; Gatifloxacin; Nanoparticles; Ofloxacin; Oxazines; Quinolones; Silicon Dioxide | 2009 |
Fluoroquinolones and postoperative endophthalmitis.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Ciprofloxacin; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ofloxacin; Phacoemulsification; Postoperative Complications; Prevalence; Quinolines | 2009 |
Fluoroquinolones and postoperative endophthalmitis.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Ciprofloxacin; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ofloxacin; Phacoemulsification; Postoperative Complications; Prevalence; Quinolines | 2009 |
Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacterial Infections; Humans; India; Male; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Retrospective Studies; Staphylococcus; Streptococcus | 2010 |
Susceptibility comparisons of normal preoperative conjunctival bacteria to fluoroquinolones.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Bacteria; Conjunctiva; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ofloxacin; Preoperative Care; Quinolines | 2009 |
Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
Topics: Aza Compounds; Clostridioides difficile; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines | 2009 |
Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Ciprofloxacin; Diclofenac; Dioxolanes; Drug Combinations; Drug Interactions; Enoxacin; Fleroxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Male; Mice; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Phenylacetates; Piperazines; Receptors, GABA-A; Seizures | 2009 |
Evaluation of the extent of protein binding by means of NMR diffusion and relaxation experiments, and automated continuous ultrafiltration.
Topics: Algorithms; Anti-Bacterial Agents; Diffusion; Fluoroquinolones; Gatifloxacin; Magnetic Resonance Spectroscopy; Nalidixic Acid; Ofloxacin; Protein Binding; Serum Albumin, Bovine; Solutions; Ultrafiltration | 2009 |
Comparison of fluoroquinolones: cytotoxicity on human corneal epithelial cells.
Topics: Anti-Infective Agents; Aza Compounds; Cell Survival; Cells, Cultured; Ciprofloxacin; Electric Impedance; Epithelial Cells; Epithelium, Corneal; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Norfloxacin; Ofloxacin; Ophthalmic Solutions; Preservatives, Pharmaceutical; Quinolines | 2010 |
Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains.
Topics: Anti-Bacterial Agents; Aza Compounds; Benzalkonium Compounds; Colony Count, Microbial; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus | 2009 |
Safety of intracameral injection of gatifloxacin, levofloxacin on corneal endothelial structure and viability.
Topics: Animals; Anterior Chamber; Anti-Infective Agents; Cell Survival; Endophthalmitis; Endothelium, Corneal; Female; Fluoroquinolones; Gatifloxacin; Injections; Levofloxacin; Male; Microscopy, Electron, Scanning; Ofloxacin; Rabbits | 2009 |
A comparative analysis of chromosomal aberrations in cultured human lymphocytes due to fluoroquinolone drugs at different expression periods.
Topics: Anti-Infective Agents; Cell Cycle; Cells, Cultured; Chromosome Aberrations; Ciprofloxacin; DNA Replication; Dose-Response Relationship, Drug; Fluoroquinolones; Gatifloxacin; Humans; Lymphocytes; Ofloxacin | 2010 |
Determination of ofloxacin and gatifloxacin by mixed micelle-mediated cloud point extraction-fluorimetry combined methodology.
Topics: Calibration; Centrifugation; Fluorometry; Fluoroquinolones; Gatifloxacin; Humans; Hydrogen-Ion Concentration; Limit of Detection; Micelles; Nephelometry and Turbidimetry; Ofloxacin; Sodium Chloride; Spectrometry, Fluorescence; Surface-Active Agents; Tablets; Temperature; Time Factors | 2010 |
In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.
Topics: Aminopyridines; Antitubercular Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium; Mycobacterium avium Complex; Mycobacterium chelonae; Mycobacterium fortuitum; Mycobacterium Infections; Mycobacterium kansasii; Mycobacterium tuberculosis; Nontuberculous Mycobacteria; Ofloxacin; Quinolines; Rifampin; Species Specificity | 2010 |
Antimicrobial susceptibility testing of newer quinolones against gram positive and gram negative clinical isolates.
Topics: Anti-Infective Agents; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin | 2010 |
Simultaneous determination of isoniazid, rifampicin, levofloxacin in mouse tissues and plasma by high performance liquid chromatography-tandem mass spectrometry.
Topics: Animals; Antibiotics, Antitubercular; Brain Chemistry; Chromatography, High Pressure Liquid; Female; Fluoroquinolones; Gatifloxacin; Intestine, Small; Isoniazid; Kidney; Least-Squares Analysis; Levofloxacin; Liver; Lung; Male; Methanol; Mice; Ofloxacin; Reproducibility of Results; Rifampin; Sensitivity and Specificity; Tandem Mass Spectrometry; Tissue Distribution | 2010 |
Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.
Topics: Animals; Antitubercular Agents; Aza Compounds; DNA Gyrase; Enoxacin; Fluoroquinolones; Gatifloxacin; Mice; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2010 |
Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.
Topics: Anti-Bacterial Agents; Aza Compounds; Binding Sites; Canada; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 2011 |
Pharmacokinetic/pharmacodynamic modelling of the bactericidal activity of free lung concentrations of levofloxacin and gatifloxacin against Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Area Under Curve; Culture Media; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Lung; Microbial Sensitivity Tests; Models, Biological; Ofloxacin; Pneumococcal Infections; Streptococcus pneumoniae | 2011 |
[The effectiveness of intraocular delivery of 5-fluoroquinolones for prophylaxis of intraocular infection].
Topics: Anti-Bacterial Agents; Aza Compounds; Eye Infections, Bacterial; Eye Injuries; Female; Fluoroquinolones; Gatifloxacin; Humans; Injections, Intraocular; Levofloxacin; Male; Military Medicine; Moxifloxacin; Ofloxacin; Quinolines; Warfare | 2011 |
In vitro comparison of the cytotoxic effects of clinically available ophthalmic solutions of fluoroquinolones on human keratocytes.
Topics: Anti-Bacterial Agents; Aza Compounds; Benzalkonium Compounds; Cells, Cultured; Corneal Keratocytes; Culture Media; Fluoroquinolones; Gatifloxacin; Humans; L-Lactate Dehydrogenase; Microscopy, Phase-Contrast; Moxifloxacin; Norfloxacin; Ofloxacin; Ophthalmic Solutions; Preservatives, Pharmaceutical; Quinolines | 2011 |
[Efficacy and tolerance of rezonizate in complex with fluoroquinolones or mycobutin on a model of experimental murine tuberculosis].
Topics: Animals; Antibiotics, Antitubercular; Disease Models, Animal; Drug Therapy, Combination; Drug Tolerance; Fluoroquinolones; Gatifloxacin; Isoxazoles; Levofloxacin; Mice; Mycobacterium tuberculosis; Ofloxacin; Oxazolidinones; Rifabutin; Tuberculosis | 2011 |
Efficacy of gemifloxacin for the treatment of experimental Staphylococcus aureus keratitis.
Topics: Animals; Anti-Infective Agents, Local; Colony Count, Microbial; Conjunctival Diseases; Cornea; Eye; Female; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Keratitis; Levofloxacin; Male; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Rabbits; Staphylococcal Infections; Staphylococcus aureus | 2012 |
[In vitro antibiotic susceptibility to fluoroquinolones].
Topics: Acanthamoeba Keratitis; Anti-Bacterial Agents; Aza Compounds; Body Fluids; Ciprofloxacin; Colombia; Conjunctivitis, Bacterial; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Eye Infections, Fungal; Eye Infections, Parasitic; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies | 2012 |
Induction of mycobacterial resistance to quinolone class antimicrobials.
Topics: Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines | 2012 |
Aluminium sensitized spectrofluorimetric determination of fluoroquinolones in milk samples coupled with salting-out assisted liquid-liquid ultrasonic extraction.
Topics: Acetonitriles; Aluminum; Ammonium Sulfate; Animals; Cattle; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Hydrogen-Ion Concentration; Limit of Detection; Liquid-Liquid Extraction; Milk; Norfloxacin; Ofloxacin; Solutions; Spectrometry, Fluorescence; Temperature; Ultrasonics; Water | 2012 |
[The changes of ocular bacterial isolates and in vitro antimicrobial susceptibility in the past six years].
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Eye; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Retrospective Studies; Staphylococcus epidermidis; Tobramycin | 2012 |
Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin.
Topics: Antitubercular Agents; Aza Compounds; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gene Expression Regulation, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Russia; Tuberculosis, Pulmonary | 2013 |
Simultaneous determination of ofloxacin and gatifloxacin on cysteic acid modified electrode in the presence of sodium dodecyl benzene sulfonate.
Topics: Benzenesulfonates; Carbon; Chemistry, Pharmaceutical; Cysteic Acid; Electrochemistry; Electrodes; Fluoroquinolones; Gatifloxacin; Humans; Ofloxacin; Oxidation-Reduction; Surface Properties; Time Factors | 2013 |
Comparison of contamination rates between preserved and preservative-free fluoroquinolone eyedrops.
Topics: Anti-Bacterial Agents; Aspergillus niger; Bacteria; Bacteriological Techniques; Benzalkonium Compounds; Candida albicans; Colony Count, Microbial; Drug Contamination; Eye Diseases; Female; Fluoroquinolones; Fungi; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Ophthalmic Solutions; Preservatives, Pharmaceutical; Prospective Studies; Pseudomonas aeruginosa; Staphylococcus aureus | 2013 |
The mechanisms of insulin secretion and calcium signaling in pancreatic β-cells exposed to fluoroquinolones.
Topics: Animals; Anti-Bacterial Agents; Calcium Signaling; Cell Line; Cricetinae; Fluoroquinolones; Gatifloxacin; Insulin; Insulin Secretion; Insulin-Secreting Cells; Levofloxacin; Ofloxacin; Tolbutamide | 2013 |
Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones.
Topics: Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Case-Control Studies; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Tuberculosis | 2013 |
Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China.
Topics: Antitubercular Agents; China; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Prevalence | 2014 |
Salmonella Typhi and Salmonella Paratyphi A elaborate distinct systemic metabolite signatures during enteric fever.
Topics: Area Under Curve; Bacterial Proteins; Biomarkers; Case-Control Studies; Fluoroquinolones; Gas Chromatography-Mass Spectrometry; Gatifloxacin; Humans; Metabolome; Metabolomics; Multivariate Analysis; Nepal; Ofloxacin; Pattern Recognition, Automated; Principal Component Analysis; Randomized Controlled Trials as Topic; ROC Curve; Salmonella paratyphi A; Salmonella typhi; Typhoid Fever | 2014 |
Undifferentiated febrile illness in Kathmandu, Nepal.
Topics: Anti-Bacterial Agents; Fever; Fluoroquinolones; Gatifloxacin; Humans; Nepal; Ofloxacin; Prospective Studies; Q Fever; Rickettsia Infections; Typhoid Fever; Typhus, Endemic Flea-Borne | 2015 |
Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.
Topics: Aminopyridines; Antitubercular Agents; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Gatifloxacin; Gene Expression; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Thailand; Tuberculosis, Pulmonary | 2016 |
Using Mycobacterium tuberculosis Single-Nucleotide Polymorphisms To Predict Fluoroquinolone Treatment Response.
Topics: Antitubercular Agents; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Polymorphism, Single Nucleotide | 2019 |
Corynebacterium Keratitis: Pure Versus Mixed Infection and Antibiotic Susceptibility Patterns From Different Tertiary Eye Care Centers.
Topics: Anti-Bacterial Agents; Cefazolin; Ciprofloxacin; Coinfection; Corynebacterium; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Keratitis; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Retrospective Studies; Tertiary Care Centers; Vancomycin | 2022 |
Fluoroquinolone resistance in bacterial isolates from ocular infections: Trend in antibiotic susceptibility patterns between 2005-2020.
Topics: Anti-Bacterial Agents; Cefuroxime; Ciprofloxacin; Colistin; Eye Infections; Fluoroquinolones; Gatifloxacin; Humans; Longitudinal Studies; Moxifloxacin; Ofloxacin; Retrospective Studies | 2022 |
Synthesis of a dual-functional terbium doped copper oxide nanoflowers for high-efficiently electrochemical sensing of ofloxacin, pefloxacin and gatifloxacin.
Topics: Copper; Electrochemical Techniques; Electrodes; Gatifloxacin; Ofloxacin; Oxides; Pefloxacin; Terbium | 2023 |